-

Hologic to Announce Financial Results for the Third Quarter of Fiscal 2023 on Monday, July 31, 2023

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2023 on Monday, July 31, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

Interested participants may listen to the call by dialing (877) 400-0505 (in the United States and Canada) or +1 (773) 305-6865 (for international callers) and referencing access code 3332917. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. A webcast replay will be available approximately two hours after the call ends.

Hologic will provide a live and webcast replay of the call on the Company’s website at investors.hologic.com. The call will be available there for 30 days.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

SOURCE: Hologic, Inc.

Contacts

Paula Izidoro
Manager, Investor Relations and Social Media
858-410-8904
paula.izidoro@hologic.com

Industry:

Hologic, Inc.

NASDAQ:HOLX
Release Versions
English
$Cashtags
$HOLX
Hashtags
#earnings
#holx

Contacts

Paula Izidoro
Manager, Investor Relations and Social Media
858-410-8904
paula.izidoro@hologic.com

Social Media Profiles
Hologic Facebook
Hologic Instagram
Hologic LinkedIN
Hologic Twitter
Hologic YouTube
More News From Hologic, Inc.

Hologic to Present New Data at ASCO 2026 Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. and its subsidiary, Biotheranostics, Inc., today announced new data demonstrating how the Breast Cancer Index® (BCI™) Test results influence extended endocrine therapy decisions for patients with early-stage, hormone receptor-positive (HR+) breast cancer. According to the latest analysis, physician recommendations for extended endocrine therapy increased by more than 30% among patients identified by the BCI Test as likely to benefit, while reco...

New Evidence Backs Hologic’s AI-Powered Mammography Technology for Detecting Challenging Cancers

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Research presented at the Society of Breast Imaging (SBI) Symposium backs Hologic AI-powered mammography technology for detecting challenging cancers....

Blackstone and TPG Complete Acquisition of Hologic

MARLBOROUGH, Mass. & NEW YORK & SAN FRANCISCO & FORT WORTH, Texas--(BUSINESS WIRE)--Blackstone and TPG Complete Acquisition of Hologic Accomplished MedTech leader Joe Almeida named Chief Executive Officer...
Back to Newsroom